Cancer Pain Management — Part 4: Adjuvant Analgesics, Interventional Approaches, and CIPN Management
Adjuvant analgesic dosing for neuropathic and bone pain, interventional pain procedures, palliative radiation, and chemotherapy-induced peripheral neuropathy prevention and treatment.
Adjuvant Analgesics
Adjuvant analgesics are medications with a primary indication other than pain that possess analgesic properties in specific pain states. They are essential components of multimodal cancer pain management, particularly for neuropathic pain, bone pain, and pain syndromes with inflammatory or compressive components. Adjuvants may be used at any step of the analgesic ladder and can reduce opioid requirements.1
Anticonvulsants for Neuropathic Pain
Anticonvulsants acting on voltage-gated calcium channels (gabapentin, pregabalin) are first-line adjuvant analgesics for cancer-related neuropathic pain, including tumor-related neuropathy, post-surgical neuropathic pain syndromes, and chemotherapy-induced peripheral neuropathy.
Gabapentin
| Parameter | Recommendation |
|---|---|
| Mechanism | Binds alpha-2-delta subunit of voltage-gated calcium channels; reduces excitatory neurotransmitter release |
| Starting dose | 100–300 mg orally at bedtime |
| Titration | Increase by 100–300 mg every 1–3 days as tolerated |
| Target dose range | 900–3600 mg/day in 3 divided doses |
| Common effective dose | 1800–2400 mg/day |
| Maximum daily dose | 3600 mg/day |
| Renal dosing adjustments | CrCl 30–59 mL/min: 200–700 mg twice daily (max 1400 mg/day); CrCl 15–29 mL/min: 200–700 mg once daily (max 700 mg/day); CrCl less than 15 mL/min: 100–300 mg once daily (max 300 mg/day); supplemental dose after hemodialysis: 125–350 mg |
| Common adverse effects | Somnolence, dizziness, peripheral edema, ataxia, weight gain |
| Onset of analgesic effect | 1–2 weeks; full effect may take 4–8 weeks |
| Notes | Non-linear absorption (bioavailability decreases at higher doses); no hepatic metabolism; no significant drug interactions; may be preferred in patients on multiple medications |
Pregabalin
| Parameter | Recommendation |
|---|---|
| Mechanism | Same mechanism as gabapentin (alpha-2-delta calcium channel subunit binding) with higher binding affinity and linear pharmacokinetics |
| Starting dose | 25–75 mg orally at bedtime, or 25–75 mg twice daily |
| Titration | Increase by 75 mg every 3–7 days as tolerated |
| Target dose range | 150–600 mg/day in 2 divided doses |
| Common effective dose | 300 mg/day |
| Maximum daily dose | 600 mg/day |
| Renal dosing adjustments | CrCl 30–60 mL/min: 75–300 mg/day in 2–3 divided doses; CrCl 15–30 mL/min: 25–150 mg/day in 1–2 doses; CrCl less than 15 mL/min: 25–75 mg once daily |
| Common adverse effects | Same as gabapentin; may have slightly faster onset of action |
| Onset of analgesic effect | 1–2 weeks |
| Notes | Linear pharmacokinetics (more predictable dose-response than gabapentin); scheduled substance in some jurisdictions (Schedule V in the US) due to euphoria potential |
Comparison: Gabapentin vs. Pregabalin
| Feature | Gabapentin | Pregabalin |
|---|---|---|
| Pharmacokinetics | Non-linear absorption | Linear absorption |
| Dosing frequency | Three times daily | Twice daily |
| Dose titration time | 1–3 weeks to therapeutic dose | 1–2 weeks to therapeutic dose |
| Cost | Generic widely available; low cost | Higher cost (brand); generics available |
| Abuse potential | Lower | Higher; Schedule V |
| Efficacy | Comparable when both reach adequate doses | Comparable |
Antidepressants for Neuropathic Pain
Serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs) are first-line adjuvant analgesics for neuropathic pain. They provide analgesia through enhancement of descending inhibitory pain pathways independent of their antidepressant effects.
Duloxetine
| Parameter | Recommendation |
|---|---|
| Mechanism | Serotonin and norepinephrine reuptake inhibition (SNRI) |
| Starting dose | 30 mg orally once daily |
| Titration | Increase to 60 mg once daily after 1 week |
| Target dose | 60 mg once daily (some patients may benefit from 120 mg/day in divided doses) |
| Maximum daily dose | 120 mg/day |
| Hepatic impairment | Avoid in severe hepatic impairment; not recommended in patients with substantial alcohol use |
| Renal impairment | Avoid if CrCl less than 30 mL/min |
| Common adverse effects | Nausea (most common, often transient; reduced by taking with food), dry mouth, constipation, somnolence, fatigue, dizziness |
| Drug interactions | CYP2D6 substrate and inhibitor; avoid with MAOIs (serotonin syndrome risk); caution with tramadol and other serotonergic agents |
| Onset of analgesic effect | 1–4 weeks |
| Notes | Only SNRI with high-quality evidence specifically for chemotherapy-induced peripheral neuropathy; recommended as first-line for CIPN treatment by multiple guidelines2 |
Tricyclic Antidepressants (TCAs)
| Agent | Starting Dose | Target Dose | Maximum Dose | Dosing Frequency |
|---|---|---|---|---|
| Amitriptyline | 10–25 mg at bedtime | 50–75 mg at bedtime | 150 mg/day | Once daily at bedtime |
| Nortriptyline | 10–25 mg at bedtime | 50–75 mg at bedtime | 150 mg/day | Once daily at bedtime |
| Desipramine | 10–25 mg at bedtime | 50–100 mg at bedtime | 150 mg/day | Once daily or divided |
TCA prescribing considerations in cancer patients:
| Concern | Recommendation |
|---|---|
| Anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision) | Can worsen opioid-induced constipation and urinary retention; use secondary amines (nortriptyline, desipramine) which have fewer anticholinergic effects |
| Sedation | May be beneficial in patients with insomnia; administer at bedtime; amitriptyline is most sedating |
| Cardiac effects | QTc prolongation; obtain baseline ECG before initiation; avoid in patients with cardiac conduction abnormalities, recent MI, or concurrent QTc-prolonging drugs; monitor ECG with dose escalation |
| Elderly patients | Start at lowest dose (10 mg); titrate slowly; nortriptyline or desipramine preferred over amitriptyline due to lower anticholinergic and sedative burden |
| Seizure risk | TCAs lower seizure threshold; use with caution in patients with brain metastases or other seizure risk factors |
| Overdose potential | Potentially lethal in overdose (cardiac toxicity); consider safety in patients with depression or suicidality; prescribe limited quantities |
Venlafaxine
| Parameter | Recommendation |
|---|---|
| Mechanism | SNRI (norepinephrine reuptake inhibition predominates at higher doses) |
| Starting dose | 37.5 mg orally once daily |
| Titration | Increase to 75 mg after 1 week; may increase to 150 mg after another week |
| Target dose for pain | 150–225 mg/day |
| Maximum daily dose | 225 mg/day (for pain; up to 375 mg/day for depression) |
| Notes | Less evidence than duloxetine for cancer-related neuropathic pain; may be considered as an alternative; extended-release formulation preferred for once-daily dosing |
Corticosteroids
Corticosteroids are versatile adjuvant analgesics in cancer pain management with multiple mechanisms of benefit: reduction of peri-tumor edema, anti-inflammatory effects, and direct modulation of nociceptive transmission. They are particularly useful for bone pain, visceral pain from hepatic capsule distension, neural compression, raised intracranial pressure, and as a component of malignant bowel obstruction management.3
Dosing by Indication
| Indication | Agent | Dose | Duration/Notes |
|---|---|---|---|
| Bone pain (acute flare / adjuvant to radiation) | Dexamethasone | 4–8 mg orally/IV once daily | Short course (5–7 days); taper over 1–2 weeks |
| Hepatic capsule pain | Dexamethasone | 4–8 mg orally/IV once daily | May require longer course; reassess every 2–4 weeks |
| Spinal cord compression (acute) | Dexamethasone | 10–16 mg IV bolus, then 4–6 mg IV/PO every 6 hours | Taper over 2–4 weeks after definitive treatment |
| Raised intracranial pressure (brain metastases) | Dexamethasone | 4–8 mg orally/IV every 6–12 hours | Taper to lowest effective dose |
| Nerve/plexus compression | Dexamethasone | 4–8 mg orally once daily | Course as needed; taper when possible |
| Malignant bowel obstruction | Dexamethasone | 6–16 mg IV/SC once daily | May continue if improves symptoms; reassess regularly |
| General cancer pain adjuvant | Dexamethasone | 2–4 mg orally once daily | Low-dose; minimal side effects short-term |
| Appetite stimulation / general wellbeing | Dexamethasone | 2–4 mg orally once daily | Time-limited benefit (2–4 weeks); long-term side effects limit duration |
Why dexamethasone is preferred: Minimal mineralocorticoid activity (less fluid retention); long half-life allows once or twice daily dosing; available in oral and parenteral formulations; no need for mineralocorticoid supplementation.
Approximate corticosteroid equivalencies (for reference):
| Corticosteroid | Equivalent Dose (mg) | Relative Anti-Inflammatory Potency | Relative Mineralocorticoid Potency | Biological Half-Life (hours) |
|---|---|---|---|---|
| Dexamethasone | 0.75 | 25 | 0 | 36–54 |
| Methylprednisolone | 4 | 5 | 0.5 | 18–36 |
| Prednisolone / Prednisone | 5 | 4 | 0.8 | 18–36 |
| Hydrocortisone | 20 | 1 | 1 | 8–12 |
Adverse effects with prolonged use (more than 2–4 weeks):
- Hyperglycemia (monitor blood glucose, especially in diabetic patients)
- Immunosuppression (increased infection risk in already immunocompromised cancer patients)
- Proximal myopathy (significant concern; exacerbates cancer-related deconditioning)
- Osteoporosis (compounding existing risk from bone metastases)
- Cushingoid features, skin fragility, poor wound healing
- GI ulceration (risk increased with concurrent NSAID use — add PPI)
- Psychiatric effects (insomnia, agitation, mood disturbance, psychosis)
- Adrenal suppression (taper required after prolonged use; do not discontinue abruptly)
Bone-Modifying Agents
Bisphosphonates
Bisphosphonates inhibit osteoclast-mediated bone resorption and reduce skeletal-related events (pathological fractures, spinal cord compression, need for radiation or surgery to bone, hypercalcemia) in patients with bone metastases. They also provide a modest direct analgesic benefit for bone pain.4
| Agent | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Zoledronic acid | 4 mg IV over at least 15 minutes | IV | Every 3–4 weeks | Most potent bisphosphonate; adjust dose for renal impairment (avoid if CrCl less than 35 mL/min); monitor renal function |
| Pamidronate | 90 mg IV over at least 2 hours | IV | Every 3–4 weeks | Alternative to zoledronic acid; longer infusion time |
| Ibandronate | 6 mg IV over 15 minutes, or 50 mg orally daily | IV or oral | Monthly (IV) or daily (oral) | Less evidence for fracture reduction than zoledronic acid |
Denosumab
| Parameter | Recommendation |
|---|---|
| Mechanism | Monoclonal antibody targeting RANK ligand; inhibits osteoclast formation and function |
| Dose (bone metastases) | 120 mg subcutaneously every 4 weeks |
| Dose (osteoporosis prevention) | 60 mg subcutaneously every 6 months (lower dose; not for metastatic bone disease) |
| Advantages over bisphosphonates | No renal dose adjustment required; can be used in renal impairment; subcutaneous administration; may be more effective than zoledronic acid for delaying first skeletal-related event |
| Key adverse effects | Hypocalcemia (supplement calcium 500 mg and vitamin D 400 IU daily); osteonecrosis of the jaw (same risk as bisphosphonates; dental evaluation before initiation); rebound bone resorption and vertebral fractures after discontinuation |
Common prescribing requirements for bone-modifying agents:
- Dental examination before initiation (risk of osteonecrosis of the jaw)
- Calcium supplementation: calcium 500–1000 mg daily plus vitamin D 400–800 IU daily (unless hypercalcemic)
- Monitoring: serum calcium, phosphate, magnesium, creatinine at baseline and periodically
- Duration: continue as long as bone metastases are present and patient has reasonable life expectancy; optimal duration beyond 2 years is debated
Topical Analgesics
Lidocaine Topical
| Formulation | Application | Notes |
|---|---|---|
| Lidocaine 5% patch | Apply up to 3 patches to painful area for 12 hours on / 12 hours off | Useful for localized neuropathic pain (post-surgical, post-herpetic); minimal systemic absorption; can be cut to fit; may apply to intact skin over painful area (does not need to be over nerve distribution) |
| Lidocaine 4% cream/gel | Apply to affected area 3–4 times daily | Topical anesthetic; useful for mucositis, localized superficial pain |
Capsaicin
| Formulation | Application | Notes |
|---|---|---|
| Capsaicin 0.025–0.075% cream | Apply to affected area 3–4 times daily | Low-concentration; initial burning sensation (may take 2–4 weeks for benefit); depletes substance P from peripheral nerve terminals |
| Capsaicin 8% patch (high concentration) | Applied by healthcare professional for 30–60 minutes; repeat every 3 months | More effective than low-concentration; single application can provide pain relief for up to 3 months; requires pretreatment with topical lidocaine to reduce application-site pain; limited evidence specifically in cancer pain; studied in CIPN |
Interventional Approaches
Interventional pain management techniques should be considered for cancer patients with pain that is inadequately controlled by systemic pharmacotherapy, or when systemic analgesics cause intolerable side effects. Early referral to a pain management specialist is recommended rather than reserving interventional approaches as a last resort.5
Nerve Blocks
Celiac Plexus Block and Neurolysis
| Parameter | Detail |
|---|---|
| Indication | Visceral abdominal pain, particularly from pancreatic cancer; also hepatic, gastric, and other upper abdominal malignancies |
| Technique | Percutaneous (CT or fluoroscopy-guided), or endoscopic ultrasound (EUS)-guided; diagnostic local anesthetic block first, followed by neurolysis if effective |
| Neurolytic agents | Absolute alcohol (50–100%), or phenol (6–10%) |
| Efficacy | Good-to-excellent pain relief in approximately 70–90% of patients with pancreatic cancer pain at short-term follow-up; declining efficacy over months as tumor progresses beyond the celiac plexus distribution |
| Complications | Transient diarrhea (common, self-limiting), orthostatic hypotension (common, usually transient), back pain at injection site; rare: paraplegia (less than 1%), pneumothorax |
| Timing | Should be considered early in pancreatic cancer when pain is a significant symptom, not reserved as a last resort; randomized trials show benefit when performed early |
Superior Hypogastric Plexus Block
| Parameter | Detail |
|---|---|
| Indication | Pelvic visceral pain from cervical, endometrial, ovarian, bladder, rectal, or prostatic cancer |
| Technique | CT or fluoroscopy-guided percutaneous approach |
| Efficacy | Approximately 60–70% of patients report significant pain relief |
Ganglion Impar (Walther) Block
| Parameter | Detail |
|---|---|
| Indication | Perineal pain from rectal, anal, or gynecological cancers |
| Technique | CT or fluoroscopy-guided; needle directed to the sacrococcygeal junction |
| Efficacy | Variable; may provide significant relief for perineal and rectal pain |
Peripheral Nerve Blocks
Peripheral nerve blocks (intercostal, paravertebral, brachial plexus, femoral, sciatic) can be useful for localized somatic or neuropathic pain. Continuous catheter techniques allow extended analgesia. Neurolytic blocks of peripheral nerves are generally avoided due to the risk of deafferentation pain, except in patients with limited life expectancy.
Neuraxial Drug Delivery
Epidural Analgesia
| Parameter | Detail |
|---|---|
| Indications | Regional pain in trunk or lower extremities not adequately controlled by systemic opioids; dose-limiting systemic opioid side effects |
| Agents | Opioid (morphine, hydromorphone, fentanyl) with or without local anesthetic (bupivacaine 0.0625–0.125%) with or without clonidine |
| Administration | Continuous epidural infusion via tunneled catheter or port; patient-controlled epidural analgesia (PCEA) |
| Duration | Weeks to months; catheter complications (migration, infection, occlusion) may limit long-term use |
Intrathecal Drug Delivery
| Parameter | Detail |
|---|---|
| Indications | Pain refractory to systemic pharmacotherapy and less invasive interventional approaches; expected survival of more than 3 months (to justify implantable pump); shorter survival may warrant externalized intrathecal catheter |
| Agents | Morphine (first-line), hydromorphone, fentanyl, ziconotide, bupivacaine, clonidine — often in combinations |
| Intrathecal-to-systemic potency ratios | Intrathecal morphine is approximately 100 times as potent as oral morphine (1 mg intrathecal approximately equal to 100 mg oral); intrathecal morphine is approximately 10 times as potent as epidural morphine |
| Delivery systems | Implantable programmable pump (for expected survival more than 3 months); externalized tunneled catheter connected to external pump (for shorter prognosis) |
| Advantages | Dramatic reduction in systemic opioid doses and side effects; precise drug delivery to spinal cord receptors |
| Complications | Catheter-related (migration, kinking, occlusion, breakage); infection (meningitis, pump pocket infection); pump-related (battery failure, programming error); granuloma formation at catheter tip (particularly with high-concentration morphine); intrathecal drug withdrawal if pump malfunction |
Ziconotide (Intrathecal)
| Parameter | Detail |
|---|---|
| Mechanism | N-type voltage-gated calcium channel blocker; non-opioid |
| Dose | Start 0.5–1.2 mcg/day intrathecally; titrate slowly (no more than 0.5 mcg/day increase, no more frequently than 2–3 times per week); usual effective dose 2.4–19.2 mcg/day |
| Maximum dose | 19.2 mcg/day |
| Adverse effects | Dizziness, nausea, confusion, cognitive impairment, gait disturbance; psychiatric effects (depression, psychosis) — more common with rapid titration |
| Notes | No respiratory depression; no tolerance development; useful in patients with opioid intolerance or opioid-refractory neuropathic pain |
Palliative Radiation Therapy for Pain
Radiation therapy is a highly effective analgesic intervention for localized cancer pain, particularly bone metastasis pain. It is considered first-line treatment for painful bone metastases causing localized symptoms.6
External Beam Radiation for Painful Bone Metastases
| Fractionation Schedule | Dose | Response Rate (Partial + Complete) | Notes |
|---|---|---|---|
| Single fraction | 8 Gy in 1 fraction | 60–75% overall response; 23–34% complete response | Equivalent overall pain relief to multi-fraction regimens; higher retreatment rate (approximately 20%); recommended for patients with limited prognosis or functional status, or for convenience |
| Short course | 20 Gy in 5 fractions | 60–75% overall response; 23–34% complete response | Common regimen; equivalent efficacy to longer courses |
| Conventional | 30 Gy in 10 fractions | 60–75% overall response; 23–34% complete response | Traditional standard; no proven superiority over shorter courses for pain |
| Longer courses | 35–40 Gy in 14–20 fractions | Similar overall response | May be preferred when tumor response (size reduction) is an additional goal, or for re-irradiation |
Key points:
- Single-fraction radiation (8 Gy) is recommended as the standard of care for uncomplicated painful bone metastases by multiple professional societies, based on robust randomized trial evidence demonstrating equivalent pain relief to multi-fraction regimens6
- Pain relief onset: typically begins within 2–4 weeks; median time to maximal response is 4–6 weeks
- Pain flare: approximately 25–40% of patients experience a transient increase in pain within the first few days after radiation; prophylactic dexamethasone 4–8 mg for 3–5 days around the time of treatment may reduce this
- Retreatment: single-fraction radiation can be repeated if pain recurs after initial response
Stereotactic Body Radiation Therapy (SBRT) for Bone Metastases
SBRT delivers a high dose of highly conformal radiation in 1–5 fractions. It is increasingly used for:
- Spinal metastases (especially re-irradiation or in close proximity to the spinal cord)
- Oligometastatic disease where local control is desired
- Radioresistant histologies (renal cell carcinoma, melanoma)
Typical doses: 16–24 Gy in 1 fraction, or 24–30 Gy in 3 fractions for spinal SBRT. Higher local control rates than conventional radiation but limited evidence for superior pain outcomes.
Radionuclide Therapy for Diffuse Bone Pain
Systemic radionuclide therapy is indicated for patients with widespread painful osteoblastic bone metastases (multiple sites) that are not amenable to localized external beam radiation.7
| Agent | Isotope Type | Dose | Mechanism | Response Rate | Key Adverse Effect |
|---|---|---|---|---|---|
| Radium-223 dichloride | Alpha emitter | 55 kBq/kg IV every 4 weeks x 6 doses | Calcium mimetic; concentrates in areas of active bone formation; short-range alpha particles destroy nearby tumor cells | Pain improvement in approximately 50–60%; also has survival benefit in metastatic castration-resistant prostate cancer | Myelosuppression (mild-moderate thrombocytopenia, neutropenia); GI symptoms |
| Strontium-89 chloride | Beta emitter | 148 MBq (4 mCi) IV, single dose; may repeat at 12+ week intervals | Calcium mimetic; concentrates in osteoblastic lesions | Pain improvement in approximately 60–80% | Myelosuppression (thrombocytopenia — nadir at 4–8 weeks; recovery by 12 weeks) |
| Samarium-153 lexidronam | Beta emitter | 37 MBq/kg (1 mCi/kg) IV, single dose | Chelated to EDTMP; concentrated at sites of active bone turnover | Pain improvement in approximately 55–70% | Myelosuppression (nadir at 3–5 weeks) |
Patient selection: Bone scan (or equivalent) should demonstrate osteoblastic uptake at the painful sites. Pure osteolytic metastases will not concentrate these agents. Adequate bone marrow reserve is required (typically: platelets above 60,000/mcL; WBC above 2,400/mcL; hemoglobin above 9 g/dL).
Vertebroplasty and Kyphoplasty
| Parameter | Detail |
|---|---|
| Indication | Painful vertebral compression fractures from metastatic disease or myeloma; pain not adequately controlled by analgesics and radiation |
| Technique | Percutaneous injection of polymethylmethacrylate (PMMA) bone cement into the vertebral body (vertebroplasty) or after balloon expansion of the vertebral body (kyphoplasty) |
| Efficacy | Rapid and significant pain relief in approximately 70–90% of cancer patients with vertebral compression fractures; faster pain relief than radiation alone |
| Timing | Can be performed as early as 2–4 weeks after fracture if pain is refractory to analgesics; can be combined with radiation |
| Complications | Cement extravasation (usually asymptomatic; rarely causes radiculopathy or spinal cord compression); pulmonary embolism (rare); infection; fracture of adjacent vertebrae |
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
CIPN is one of the most common and disabling treatment-related complications of cancer therapy, affecting patients during and often long after completion of chemotherapy. It is a significant cause of dose reduction, treatment delay, and early discontinuation of effective anticancer therapy, and it imposes a major burden on cancer survivors.8
Agents Commonly Causing CIPN
| Drug Class | Specific Agents | Incidence | Neuropathy Characteristics |
|---|---|---|---|
| Platinum compounds | Cisplatin | 30–70% (dose-dependent; cumulative dose above 300 mg/m2) | Predominantly sensory; large-fiber involvement; proprioception loss; dose-limiting; may worsen after treatment completion (“coasting”) |
| Oxaliplatin | 65–98% (acute cold-induced); 10–30% chronic | Acute: cold-triggered dysesthesias in hands, feet, perioral region (hours to days, self-limiting); Chronic: cumulative sensory neuropathy; coasting phenomenon | |
| Carboplatin | Lower incidence than cisplatin | Mild sensory neuropathy; usually with prolonged therapy | |
| Taxanes | Paclitaxel | 30–70% (dose-dependent) | Sensory predominant (numbness, tingling, pain in stocking-glove distribution); may have motor component; onset during treatment; dose-dependent |
| Docetaxel | 10–40% | Similar to paclitaxel but generally less severe | |
| Nab-paclitaxel | 40–70% | Similar to paclitaxel | |
| Vinca alkaloids | Vincristine | 30–50% | Sensory and motor; distal weakness (foot drop, hand grip weakness); autonomic neuropathy (constipation, ileus); most neurotoxic of the vinca alkaloids |
| Vinblastine | 5–20% | Less neurotoxic than vincristine | |
| Vinorelbine | 10–30% | Mild-moderate sensory neuropathy | |
| Proteasome inhibitors | Bortezomib | 30–65% | Painful sensory neuropathy; dose-limiting; may have motor component; subcutaneous route has lower neuropathy incidence than IV |
| Carfilzomib | Lower than bortezomib | Mild sensory neuropathy | |
| Immunomodulatory agents | Thalidomide | 25–75% (cumulative; duration-dependent) | Predominantly sensory; may be irreversible; increases with cumulative dose and duration above 6 months |
| Lenalidomide | 5–20% | Significantly lower neuropathy risk than thalidomide | |
| Antibody-drug conjugates | Brentuximab vedotin | 40–60% | Sensory and motor neuropathy; due to the MMAE (auristatin) component |
| Enfortumab vedotin | 40–50% | Similar mechanism | |
| Miscellaneous | Eribulin | 20–35% | Sensory predominant |
Prevention of CIPN
There is currently no agent with strong evidence for CIPN prevention. Multiple agents have been studied and found to be ineffective or to have insufficient evidence:9
| Agent Studied | Evidence for Prevention | Current Recommendation |
|---|---|---|
| Duloxetine | Insufficient evidence for prevention (only for treatment) | Not recommended for prevention |
| Calcium and magnesium infusions | Mixed results; initial promise for oxaliplatin neuropathy not confirmed in larger trials | Insufficient evidence to recommend |
| Glutamine | Insufficient evidence | Not recommended |
| Acetyl-L-carnitine | No benefit; one trial showed worsening neuropathy | Not recommended (potential harm) |
| Vitamin E | Inconsistent results | Not recommended |
| Amifostine | No convincing benefit | Not recommended |
| Venlafaxine | Limited evidence for acute oxaliplatin neuropathy prevention | Insufficient evidence to recommend broadly |
| Cryotherapy (frozen gloves/socks) | Emerging evidence for taxane-induced CIPN | May be offered; further study needed |
| Compression therapy (tight-fitting gloves/socks) | Emerging evidence for taxane-induced CIPN | May be offered; further study needed |
Primary prevention strategy: dose modification. The most effective approach to preventing severe, irreversible CIPN is careful monitoring with dose reduction or discontinuation of the offending agent at early signs of neuropathy, balanced against the oncological benefit of continued treatment.
Treatment of Established CIPN
Duloxetine (First-Line Pharmacotherapy)
Duloxetine is the only agent with moderate-quality evidence supporting efficacy for the treatment of established CIPN, based on a randomized, placebo-controlled, crossover trial in patients with painful CIPN from oxaliplatin or paclitaxel.10
| Parameter | Recommendation |
|---|---|
| Dose | Start 30 mg daily for 1 week, then increase to 60 mg daily |
| Evidence | Mean reduction of 1.06 points on BPI average pain score vs. placebo (statistically and clinically significant) |
| Duration | Minimum 5-week trial to assess benefit |
| Strength of recommendation | Moderate (recommended by multiple professional societies as first-line) |
Other Agents for CIPN Treatment (Limited Evidence)
| Agent | Dose | Evidence Level | Notes |
|---|---|---|---|
| Gabapentin | 900–3600 mg/day in divided doses | Low-quality; inconsistent results | Commonly used despite limited evidence; reasonable trial in patients who do not respond to duloxetine |
| Pregabalin | 150–600 mg/day in divided doses | Very limited evidence in CIPN specifically | Extrapolated from general neuropathic pain evidence |
| Tricyclic antidepressants (nortriptyline, amitriptyline) | 10–75 mg at bedtime | Limited evidence in CIPN; negative in one randomized trial | May be tried if other agents fail; anticholinergic side effects limit use |
| Topical baclofen/amitriptyline/ketamine cream | Compounded preparation applied to affected areas | Pilot study evidence only | Limited availability; considered by some for refractory cases |
| Capsaicin 8% patch | Applied to affected area for 30 min | Limited evidence; small studies | May be considered for localized painful CIPN |
| Scrambler therapy (cutaneous electrostimulation) | Non-pharmacological device-based therapy | Small randomized trials suggest benefit | Limited availability; may be offered at specialized centers |
| Acupuncture | Individualized treatment protocol | Emerging evidence; small randomized trials suggest benefit | May be offered as complementary therapy |
| Exercise (regular physical activity) | Aerobic and balance training | Growing evidence supports benefit for CIPN symptoms and function | Recommended as part of comprehensive management |
CIPN Assessment and Monitoring
- Screen for CIPN symptoms at each treatment visit using a standardized tool
- Common grading system: Common Terminology Criteria for Adverse Events (CTCAE) peripheral neuropathy grading
- Grade 1: Asymptomatic; loss of deep tendon reflexes or paresthesia
- Grade 2: Moderate symptoms; limiting instrumental activities of daily living (ADLs)
- Grade 3: Severe symptoms; limiting self-care ADLs
- Grade 4: Life-threatening consequences; urgent intervention indicated
- Patient-reported outcome tools: EORTC QLQ-CIPN20, FACT/GOG-Ntx
- Dose modifications for CIPN are agent-specific; consult individual drug references
- Document: grade of neuropathy, symptoms, functional impact, dose modifications made, and treatments prescribed
References
Fallon M, Giusti R, Aielli F, et al. “Management of Cancer Pain in Adult Patients: ESMO Clinical Practice Guidelines.” Annals of Oncology, 29(suppl 4): iv166–iv191, 2018. European Society for Medical Oncology (ESMO). ↩︎
Smith EML, Pang H, Cirrincione C, et al. “Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.” JAMA, 309(13): 1359–1367, 2013. DOI: 10.1001/jama.2013.2813 ↩︎
Paulsen Ø, Aass N, Kaasa S, Dale O. “Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review.” Journal of Pain and Symptom Management, 46(1): 96–105, 2013. DOI: 10.1016/j.jpainsymman.2012.06.019 ↩︎
Lipton A, Fizazi K, Stopeck AT, et al. “Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.” European Journal of Cancer, 48(16): 3082–3092, 2012. DOI: 10.1016/j.ejca.2012.08.002 ↩︎
Deer TR, Pope JE, Hayek SM, et al. “The Polyanalgesic Consensus Conference (PACC): Recommendations on intrathecal drug infusion systems best practices and guidelines.” Neuromodulation, 20(2): 96–132, 2017. DOI: 10.1111/ner.12538 ↩︎
Chow R, Hoskin P, Schild SE, et al. “Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis.” Radiotherapy and Oncology, 141: 56–61, 2019. DOI: 10.1016/j.radonc.2019.06.037 ↩︎ ↩︎
Parker C, Nilsson S, Heinrich D, et al. “Alpha emitter radium-223 and survival in metastatic prostate cancer.” New England Journal of Medicine, 369(3): 213–223, 2013. DOI: 10.1056/NEJMoa1213755 ↩︎
Seretny M, Currie GL, Sena ES, et al. “Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.” Pain, 155(12): 2461–2470, 2014. DOI: 10.1016/j.pain.2014.09.020 ↩︎
Loprinzi CL, Lacchetti C, Bleeker J, et al. “Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update.” Journal of Clinical Oncology, 38(28): 3325–3348, 2020. American Society of Clinical Oncology (ASCO). DOI: 10.1200/JCO.20.01399 ↩︎
Smith EML, Pang H, Cirrincione C, et al. “Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.” JAMA, 309(13): 1359–1367, 2013. Alliance for Clinical Trials in Oncology (CALGB 170601). DOI: 10.1001/jama.2013.2813 ↩︎